Innosuisse Awards CorFlow a CHF 1.7M Public Grantadmin
The Innosuisse Grant is Awarded to CorFlow for the MOCA I Clinical Trial and Translational Research
Baar, Switzerland, November 30th 2018
CorFlow Therapeutics AG (“CorFlow”) today announced that Innosuisse, the Swiss Innovation Agency, has awarded the Company a non-dilutive public grant. The grant is a continuation of the successfully completed non-clinical project which was granted by CTI/Innosuisse in January 2017. Innosuisse’s role is to promote science-based innovation in the interests of industry and society in Switzerland. The total grant is CHF 1.7M (USD 1.7M) and runs over 2 years.
The project “Translational development of a medical device to treat microvascular obstruction in heart attack patients” is in cooperation with Prof. Dominik Obrist (University of Bern, ARTORG Center of Biomedical Engineering Research), Prof. André Bernard (University of Applied Sciences Buchs NTB), Prof. Sebastian Kozerke (University and ETH Zurich, Inst. for Biomedical Engineering), Dr.med.vet. Nikola Cesarovic (University Hospital Zürich, Division of Surgical Research) and Prof. Marco Valgimigli (Bern University Hospital, Inselspital).
The project lead Prof. Obrist said: “We are grateful that Innosuisse recognised our vision for the technology’s potential to be moved to the next stage, by providing funding for the project at this pivotal stage. With the financial contributions from Innosuisse and CorFlow, the project will allow us to further deepen our understanding of the coronary microcirculation. The unique, interdisciplinary research consortium brings together unique capabilities in magnetic resonance imaging, circulatory modelling, non-clinical research and clinical trials which will be instrumental to bring the CorFlow technology into the hands of clinicians and to impact patient care”.
Prof. Valgimigli, who is the principal investigator of the First-in-Man (FIM) clinical trial to be conducted in Switzerland, commented: “Microvascular obstruction is an unmet need for acute heart attack patients and we have to date not had tools to promptly diagnose it and treat it in patients after stent placement. We are excited to join the consortium and take the lead on the clinical implementation of the CorFlow technology”.
In addition to the Innosuisse grant, CorFlow is contributing substantial funds for the continued technical and clinical development of the first generation CorFlow Controlled Flow Infusion (CoFITM) console and rapid exchange (RX) catheter. The dossier for the FIM clinical trial called MOCA I (Microvascular Obstruction with the CoFI System Assessment) has been submitted for approval to Swiss authorities. The Company targets enrolment of the first patient in the MOCA I trial in 2019 and will provide regular updates on the progress of the study.
Jon H. Hoem, CorFlow’s CEO and co-Founder, commented: “The continued and substantial support from Innosuisse is very welcome and the project will form the basis for a Swiss expert centre studying the human microcirculation. Further non-clinical and clinical research are needed to deepen our understanding of the human microcirculation and CorFlow is pleased to be a part of these efforts. We look forward to continue and expand our cooperation with scientists world-wide who share our passion for a deeper understanding of effective treatments of microvascular dysfunction which affects hundreds of thousands of patients every year”.
MVO and the Implications
Timely reperfusion using a stent in patients with acute myocardial infarction (AMI) salvages myocardium and reduces mortality. However, successful restoration of epicardial coronary artery patency after prolonged occlusion does not always lead to adequate reperfusion at the microvascular level (see red marked MVO area above).
This phenomenon, known as no-reflow or microvascular obstruction (MVO), is observed experimentally and clinically. Accurate detection, quantification and treatment of MVO are important, because clinical studies have shown that MVO is independently associated with adverse ventricular remodelling and short- and long-term patient prognosis. Multiple large clinical trials have documented that MVO is an independent factor which influences complication rates such as heart failure and death.
These clinical trials have documented that around half of all acute heart attack patients have MVO as documented by Magnetic Resonance Imaging (MRI). This translates into around 200,000 patients per year and 25% of these patients will be in heart failure after four years. MVO is therefore a major contributor to the rising costs for taking care of heart failure patients.
CorFlow aims to develop and bring to market technologies which can address this large unmet medical need. To date the company has developed the first generation console and catheter of the Controlled Flow Infusion (CoFI) technology. Non-clinical findings are promising and have in 2018 been published at leading cardiovascular conferences such at American Association of Cardiology (ACC), EuroPCR, European Society of Cardiology (ESC) and the Transcatheter Cardiovascular Therapeutics (TCT) conference.